APGEHealthcareMid-Cap
Apogee Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Apogee Therapeutics, Inc. (APGE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are APGE insiders buying or selling?
Apogee Therapeutics, Inc. insiders reported 3 open-market buys ($80.7M) and 61 sells ($186.8M) across 64 Form 4 filings — a net selling position of $106.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 11, 2026)
Total Form 4 filings
64
SEC EDGAR
Insider filers
6
Insider buys (3)
$80.7M
Insider sells (61)
$186.8M
Insider sentiment
Net sellingNet insider flow of $106.1M in net selling.
Recent APGE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 11, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $133.63 | $2.7M |
| Jul 3, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $132.74 | $730.1K |
| Jun 25, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 26.4K | $132.60 | $3.5M |
| Jun 25, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 80.0K | $132.54 | $10.6M |
| Jun 12, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $83.38 | $1.7M |
| Jun 6, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $78.71 | $432.9K |
| May 16, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $82.09 | $1.6M |
| May 9, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $84.14 | $462.8K |
| May 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $82.04 | $164.1K |
| Apr 18, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $90.00 | $180.0K |
| Apr 11, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $82.58 | $1.7M |
| Apr 4, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $84.84 | $466.6K |
| Apr 4, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $85.01 | $170.0K |
| Mar 28, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $85.00 | $170.0K |
| Mar 14, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $74.78 | $1.5M |
| Mar 7, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $71.06 | $390.8K |
| Mar 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $70.22 | $140.4K |
| Feb 14, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $63.35 | $1.3M |
| Feb 5, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 5.5K | $65.79 | $361.9K |
| Feb 5, 2026 | Jane Henderson | Chief Financial Officer | Sale | 2.0K | $65.81 | $131.6K |
| Jan 23, 2026 | Tomas Kiselak | Director | Sale | 1.8M | $76.30 | $133.5M |
| Jan 17, 2026 | Michael Thomas Henderson | Chief Executive Officer | Sale | 20.0K | $81.11 | $1.6M |
| Jan 10, 2026 | Carl Dambkowski | Chief Medical Officer | Sale | 18.7K | $77.84 | $1.5M |
| Jan 7, 2026 | Jane Henderson | Chief Financial Officer | Sale | 8.0K | $76.14 | $609.1K |
| Dec 24, 2025 | Jane Henderson | Chief Financial Officer | Sale | 1.5K | $80.00 | $120.0K |
Showing the 25 most recent of 64 Form 4 filings for Apogee Therapeutics, Inc..
Most active APGE insiders
- Carl Dambkowski27 filings
- Michael Thomas Henderson20 filings
- Jane Henderson13 filings
- Tomas Kiselak2 filings
- Mark C. Mckenna1 filing
Ask anything about APGE insider activity
Use Trabud's AI agent to query Apogee Therapeutics, Inc.'s Form 4 history in plain English — "Show me APGE CEO purchases this year" or compare it against any other ticker.
Open the AI agentAPGE insider trading FAQ
Are Apogee Therapeutics, Inc. insiders buying or selling?
Across 64 SEC Form 4 filings, Apogee Therapeutics, Inc. (APGE) insiders reported 3 open-market purchases totaling $80.7M and 61 sales totaling $186.8M. That is a net selling position of $106.1M.
How many insiders trade APGE stock?
6 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Apogee Therapeutics, Inc.. The most recent filing was accepted on Jul 11, 2026.
Where does Trabud get APGE insider trading data?
All APGE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.